156 related articles for article (PubMed ID: 36760683)
1. FNBP4 is a Potential Biomarker Associated with Cuproptosis and Promotes Tumor Progression in Hepatocellular Carcinoma.
Zheng KW; Zhang CH; Wu W; Zhu Z; Gong JP; Li CM
Int J Gen Med; 2023; 16():467-480. PubMed ID: 36760683
[TBL] [Abstract][Full Text] [Related]
2. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
3. FBXO43 increases CCND1 stability to promote hepatocellular carcinoma cell proliferation and migration.
Li CM; Zhang J; Wu W; Zhu Z; Li F; Wu D; Wang XJ; Xie CM; Gong JP
Front Oncol; 2023; 13():1138348. PubMed ID: 36937431
[TBL] [Abstract][Full Text] [Related]
4. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response.
Ma YL; Yang YF; Wang HC; Yang CC; Yan LJ; Ding ZN; Tian BW; Liu H; Xue JS; Han CL; Tan SY; Hong JG; Yan YC; Mao XC; Wang DX; Li T
Front Pharmacol; 2023; 14():1101749. PubMed ID: 36909185
[No Abstract] [Full Text] [Related]
5. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma.
Zhang Q; Ma L; Zhou H; Zhou Y; Liu S; Li Q
Front Oncol; 2022; 12():1040736. PubMed ID: 36324575
[TBL] [Abstract][Full Text] [Related]
6. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
7. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
PeerJ; 2021; 9():e11342. PubMed ID: 33987018
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic and Drug-targeting Value of Lymphoid Enhancer-binding Factor-1 in Hepatocellular Carcinoma.
Guo R; Dai H; Liu F; Liu M; Li X; Li T; Liao J; Chen ZS; Liu Y; Fang S
Recent Pat Anticancer Drug Discov; 2022; 18(2):211-223. PubMed ID: 36045537
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
11. A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients.
Bai WD; Liu JY; Li M; Yang X; Wang YL; Wang GJ; Li SC
World J Oncol; 2022 Oct; 13(5):299-310. PubMed ID: 36406193
[TBL] [Abstract][Full Text] [Related]
12. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
13. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
[TBL] [Abstract][Full Text] [Related]
15. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
16. The expression of cuproptosis-related genes in hepatocellular carcinoma and their relationships with prognosis.
Zhao X; Chen J; Yin S; Shi J; Zheng M; He C; Meng H; Han Y; Han J; Guo J; Yuan Z; Wang Y
Front Oncol; 2022; 12():992468. PubMed ID: 36313717
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
18. A prognostic model for hepatocellular carcinoma based on apoptosis-related genes.
Liu R; Wang G; Zhang C; Bai D
World J Surg Oncol; 2021 Mar; 19(1):70. PubMed ID: 33712023
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma.
Cong T; Luo Y; Liu Y; Yang C; Yang H; Li Y; Li J; Li X
Front Genet; 2022; 13():1000997. PubMed ID: 36276933
[TBL] [Abstract][Full Text] [Related]
20. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]